Welcome to our dedicated page for Skinhealth Systems news (Ticker: SKIN), a resource for investors and traders seeking the latest updates and insights on Skinhealth Systems stock.
SkinHealth Systems Inc. reports developments tied to its global medical aesthetics business, with recurring updates on financial results, margin performance, adjusted EBITDA, installed-base activity and its recurring consumables model. The company, formerly The Beauty Health Company, trades on the Nasdaq Capital Market under the symbol SKIN.
Company news also covers the Hydrafacial platform, SkinStylus microneedling and nano-channeling treatments, HydraScalp with Keravive, provider adoption, consumer skin-health research, board appointments and the completed corporate rebrand to SkinHealth Systems.
SkinHealth Systems (NASDAQ: SKIN), home to Hydrafacial, launched Hydrafacial Impact, a national provider education program aimed at helping aesthetic practices maximize their Hydrafacial investment and support sustainable, profitable growth. The inaugural series will visit nine U.S. markets through the end of 2026, including New York and Long Beach.
Hydrafacial Impact focuses on operational drivers of practice performance, covering membership program best practices, combination treatment protocols, personalization techniques and ROI-focused strategies. It extends SkinHealth Systems’ broader education platform, which has trained more than 60,000 providers worldwide through certifications, dinner series, in-office trainings, webinars and over 120 on-demand programs.
SkinHealth Systems (NASDAQ: SKIN) reported Q2 2026 net sales of $72.1 million, down 7.8% year over year, as both delivery systems and consumables declined. The company placed 770 delivery systems versus 957 a year ago, while the active install base increased to 36,516.
GAAP gross margin rose to 68.4% from 62.8%, and adjusted gross margin to 71.8%. Operating expenses fell to $45.8 million, supporting adjusted EBITDA of $17.0 million (23.6% margin), up from $13.9 million. Net loss was $(2.7) million versus prior net income of $19.7 million, mainly reflecting a prior-year $18.1 million gain on 2026 notes.
For Q3 2026, the company guides net sales of $65–$70 million and adjusted EBITDA of $5–$7 million. For full-year 2026, it forecasts net sales of $280–$290 million and adjusted EBITDA of $39–$46 million, assuming stable market conditions and ongoing cost discipline.
SkinHealth Systems (NASDAQ: SKIN) will release its second quarter 2026 financial results after market close on Thursday, August 6, 2026, followed by an investor conference call at 4:30 p.m. Eastern Time. A live webcast, supporting materials, and a replay will be available on the company’s investor relations website.
SkinHealth Systems (NASDAQ: SKIN) received new FDA clearance for the SkinStylus SteriLock MicroSystem to improve the appearance of periorbital wrinkles in adults 22+ across all Fitzpatrick skin types.
SkinStylus is now the only microneedling device with FDA-cleared indications for facial acne scars, periorbital wrinkles, and abdominal hypertrophic scars, supporting its role alongside Hydrafacial treatments in a rapidly growing U.S. microneedling market estimated at $330 million in 2025.
5W AI Communications released the Med Spa & Aesthetic Medicine AI Visibility Index 2026, measuring how major AI answer engines route aesthetic medicine patients to brands and providers.
The study finds AbbVie/Allergan and Galderma control 80% of drug and device AI citation share, while Hydrafacial (NASDAQ: SKIN) and other device makers do not appear in the top 25.
SkinHealth Systems (NASDAQ: SKIN) introduced HydraScalp® with Keravive™, a refreshed, professional, non-invasive scalp treatment using Hydrafacial’s Vortex-Fusion™ Technology and biomimetic peptides to cleanse, exfoliate and nourish the scalp.
The treatment adds newly engineered Purify™ and Nourish™ tips for better contact, suction, exfoliation and serum delivery, aiming to improve scalp health and the appearance of fuller, thicker-looking hair, with clinical findings supporting visible benefits.
SkinHealth Systems (NASDAQ: SKIN) reported Q1 2026 results: net sales $64.9M (down 6.7% YoY), net loss $(6.6)M versus $(10.1)M, and adjusted EBITDA $8.5M versus $7.3M. The company placed 746 delivery systems and reported an active install base of 36,419.
Cash and equivalents were $204.4M at March 31, 2026. SkinHealth lowered full‑year 2026 net sales guidance to $280–$295M and maintained adjusted EBITDA guidance of $35–$45M.
SkinHealth Systems (NASDAQ: SKIN) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. The company will host an investor conference call at 4:30 p.m. ET following a press release with results.
A live webcast and supporting materials will be available in the investor relations section of the company website at www.skinhealthsystems.com. A recording will be posted about three hours after the call concludes. The company uses SEC filings, press releases and public calls to disclose material information.
SkinHealth Systems (Nasdaq: SKIN) appointed three independent directors—Kenneth Tripp, Dr. Sachin Shridharani, and E. Scott Beattie—effective April 17, 2026.
Each appointee brings sector expertise: medtech operations (Tripp), clinical aesthetics and trial experience (Shridharani), and global consumer brand leadership (Beattie). The Board currently totals 11 members and is expected to be nine after the 2026 Annual Meeting.
SkinHealth Systems (NASDAQ: SKIN) is the new corporate name for The Beauty Health Company, effective immediately with Nasdaq reflecting the change on April 23, 2026.
The rebrand signals a shift to a clinically driven, science-backed medical aesthetics platform while retaining Hydrafacial as its flagship and continuing to trade under the ticker SKIN.
The company emphasizes a device-plus-consumables model, a focus on device utilization, and a global installed base of more than 36,000 devices.